Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer

Breast Cancer Research

Edison T Liu⁵  Steven K Libutti³  Chandramouli Gadisetti¹  Laura Assersohn²  Andrew L Feldman³  Amir A Jazaeri¹  Mitch Dowsett²  Trevor J Powles²  Christos Sotiriou⁴ 

[1] Division of Clinical Sciences, Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, USA;Royal Marsden NHS Trust Hospital, London & Surrey, UK;Surgical Branch, National Cancer Institute, National Institutes of Health, Gaithersburg, USA;Chemotherapy Unit, Microarray Facility, Jules Bordet Institute, Free University of Brussels, Brussels, Belgium;Genome Institute of Singapore, Singapore

关键词: gene expression;    fine needle aspiration;    chemotherapy;    cDNA microarray;    breast cancer;   

Others  :  1118831
DOI  :  10.1186/bcr433

 received in 2001-11-27, accepted in 2002-03-04,  发布年份 2002

【 摘 要 】

Background

Drug resistance in breast cancer is a major obstacle to successful chemotherapy. In this study we used cDNA microarray technology to examine gene expression profiles obtained from fine needle aspiration (FNA) of primary breast tumors before and after systemic chemotherapy. Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response.

Methods

Repeat presurgical FNA samples were taken from six patients who were to undergo primary surgical treatment. Additionally, a group of 10 patients who were to receive neoadjuvant chemotherapy underwent two FNAs before chemotherapy (adriamycin 60 mg/m² and cyclophosphamide 600 mg/m²) followed by another FNA on day 21 after the first cycle. Total RNA was amplified with T7 Eberwine's procedure and labeled cDNA was hybridized onto a 7600-feature glass cDNA microarray.

Results

We identified candidate gene expression profiles that might distinguish tumors with complete response to chemotherapy from tumors that do not respond, and found that the number of genes that change after one cycle of chemotherapy was 10 times greater in the responding group than in the non-responding group.

Conclusion

This study supports the suitability of FNA-derived cDNA microarray expression profiling of breast cancers as a comprehensive genomic approach for studying the mechanisms of drug resistance. Our findings also demonstrate the potential of monitoring post-chemotherapy changes in expression profiles as a measure of pharmacodynamic effect and suggests that these approaches might yield useful results when validated by larger studies.

【 授权许可】

   
2002 BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998, 352:930-942.
• [2]Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999, 17:3058-3063.
• [3]Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M: Pre-operative chemotherapy induces apoptosis in early breast cancer. Lancet 1997, 349:849.
• [4]Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000, 89:2145-2152.
• [5]Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-5984.
• [6]Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
• [7]Sotiriou C, Chand K, Petersen D, Jazaeri A, Liu ET: Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002, 4:30-36.
• [8]Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M, Coleman P: Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 1992, 89:3010-3014.
• [9]Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18:457-459.
• [10]Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868.
• [11]Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloom-field CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
• [12]He Q, Liang CH, Lippard SJ: Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000, 97:5768-5772.
• [13]Arioka H, Nishio K, Ishida T, Fukumoto H, Fukuoka K, Nomoto T, Kurokawa H, Yokote H, Abe S, Saijo N: Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. Jpn J Cancer Res 1999, 90:108-115.
• [14]Desagher S, Martinou JC: Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000, 10:369-377.
• [15]Muller I, Niethammer D, Bruchelt G: Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1998, 1:491-494.
• [16]Denis-Gay M, Petit JM, Mazat JP, Ratinaud MH: Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells. Biochem Pharmacol 1998, 56:451-457.
• [17]Naot D, Sionov RV, Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997, 71:241-319.
• [18]Costa S, Terzano P, Bovicelli A, Martoni A, Angelelli B, Santini D, Ceccarelli C, Lipponen P, Erzen M, Syrjanen S, Syrjanen K: CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001, 80:67-73.
• [19]Foskett SM, Ghose R, Tang DN, Lewis DE, Rice AP: Antiapoptotic function of CDK9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001, 75:1220-1228.
• [20]Luparello C, Avanzato G, Carella C, Pucci-Minafra I: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999, 54:235-244.
• [21]Schroder JK, Seidelmann M, Kirch HC, Seeber S, Schutte J: Assessment of resistance induction to cytosine arabinoside following transfer and overexpression of the deoxycytidylate deaminase gene in vitro. Leukoc Res 1998, 22:619-624.
• [22]Tukey JW: Tightening the clinical trial. Control Clin Trials 1993, 14:266-285.